Over recent years, complete or partial loss of parafibromin expression has been reported in HPT-JT, parathyroid, colorectal, and lung cancer, and its expression has been negatively associated with tumor aggressiveness and poor prognosis [18,19,21,23,30]. Here, CDC73 is linked to lung cancer.